Vedolizumab for children with intestinal graft-versus-host disease: a case report and literature review

Fukuta, Tadashi; Muramatsu, Hideki; Yamashita, Daisuke; Sajiki, Daichi; Maemura, Ryo; Tsumura, Yusuke; Yamamori, Ayako; Imaya, Masayuki; Wakamatsu, Manabu; Nishikawa, Eri; Narita, Kotaro; Kataoka, Shinsuke; Taniguchi, Rieko; Narita, Atsushi; Nishio, Naomichi; Takahashi, Yoshiyuki

doi:10.1007/s12185-023-03590-2

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two of these patients experienced a complete response ( 115 ). Rosa et al reported 3 pediatric patients with oncological diseases and grade IV gut aGvHD, of whom only one achieved GvHD remission and Fukuta et al reported 1 patient with a clinical response to vedolizumab ( 116 , 117 ). Aldouby Bier reported on 13 pediatric patients with SR gut aGvHD treated with vedolizumab, among whom 8 presented a clinical recovery and 2 had ongoing chronic colitis.…”

Section: Monoclonal Antibodiesmentioning

confidence: 99%

Treatment of steroid-refractory graft versus host disease in children

Gottardi,

Leardini,

Muratore

et al. 2023

Front. Transplant.

View full text Add to dashboard Cite

Systemic steroids are still the first-line approach in acute graft-versus-host disease (aGvHD), and the backbone of chronic GvHD management. Refractoriness to steroid represent a major cause of morbidity and non-relapse mortality after hematopoietic stem cell transplantation (HSCT). In both backgrounds, several second-line immunosuppressive agents have been tested with variable results in terms of efficacy and toxicity. Solid evidence regarding these approaches is still lacking in the pediatric setting where results are mainly derived from adult experiences. Furthermore, the number of treated patients is limited and the incidence of acute and chronic GvHD is lower, resulting in a very heterogeneous approach to this complication by pediatric hematologists. Some conventional therapies and anti-cytokine monoclonal antibodies used in the adult setting have been evaluated in children. In recent years, the increasing understanding of the biological mechanisms underpinning the pathogenesis of GvHD justified the efforts toward the adoption of targeted therapies and non-pharmacologic approaches, with higher response rates and lower immunosuppressive effects. Moreover, many questions regarding the precise timing and setting in which to integrate these new approaches remain unanswered. This Review aims to critically explore the current evidence regarding novel approaches to treat SR-GvHD in pediatric HSCT recipients.

show abstract

Section: Monoclonal Antibodiesmentioning

confidence: 99%